InventisBio Co., Limited (SHA:688382)

Market Cap	23.50B
Revenue (ttm)	168.37M
Net Income (ttm)	-214.53M
Shares Out	578.33M
EPS (ttm)	-0.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,023,408
Average Volume	12,953,201
Open	41.92
Previous Close	41.84
Day's Range	39.28 - 41.92
52-Week Range	6.67 - 49.68
Beta	0.48
RSI	50.36
Earnings Date	Aug 23, 2025

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China and the United States. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; D-0502, which is in Phase I clinical trial for the breast cancer indications; and D-1553, which in Phase I clinical trial for NSCLS, colorectal cancer indications. Its drug candidates for the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 185
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688382

Financial Performance

In 2024, InventisBio's revenue was 168.79 million, a decrease of -9.02% compared to the previous year's 185.53 million. Losses were -240.20 million, -15.41% less than in 2023.